Loading...

Loading...

GLP-1: How Weight-Loss Drugs Are Rewriting Diagnostics Demand
GLP-1: How Weight-Loss Drugs Are Rewriting Diagnostics Demand
By Hector Barillas - Thu, 09/10/2026 - 05:30
Mexico's GLP-1 expansion requires parallel diagnostic testing to track cardiometabolic outcomes effectively, writes Héctor Barillas.
https://mexicobusiness.news/tag/eli-lilly
More Health
Reshaping Chronic Disease Management: From Pipeline to Prevention
Reshaping Chronic Disease Management: From Pipeline to Prevention
By Fernando Mares - Wed, 09/09/2026 - 11:46
Mexico's chronic disease burden is pushing regulators and pharma toward a preventive model built on access, digital tools, and early detection.
AI, Biomarkers and Drug Design
AI, Biomarkers and Drug Design
By Luis Alberto Velez - Mon, 07/27/2026 - 07:30
AI in precision oncology drives drug design, biomarker discovery, and smarter trials to reduce biological uncertainty, writes Luis Velez.
Mexico's Obesity Response Becomes a Business Inflection Point
Mexico's Obesity Response Becomes a Business Inflection Point
By Sergio Arturo Lievano Madrigal - Thu, 07/16/2026 - 16:51
While Mexico's obesity response is advancing across several tracks simultaneously, many companies are already adjusting their investment strategy.

GLP-1 Market Expands Beyond Weight Loss
GLP-1 Market Expands Beyond Weight Loss
By Sergio Arturo Lievano Madrigal - Fri, 05/22/2026 - 15:20
New research and pharmaceutical initiatives are pushing GLP-1 therapies beyond obesity treatment and deeper into healthcare systems.
Lilly to Acquire Kelonia in US$7 Billion Oncology Expansion
Lilly to Acquire Kelonia in US$7 Billion Oncology Expansion
By Aura Moreno - Mon, 04/20/2026 - 13:28
Lilly’s US$7 billion acquisition of Kelonia expands oncology capabilities and reflects broader pharma diversification.
Lilly’s Oral GLP-1 Candidate Outperforms Semaglutide in Trial
Lilly’s Oral GLP-1 Candidate Outperforms Semaglutide in Trial
By Aura Moreno - Mon, 03/02/2026 - 08:50
Lilly’s oral GLP-1 orforglipron surpassed semaglutide in A1C reduction and weight loss, reshaping the oral cardiometabolic market.
Innovation That Expands Access to Life-Saving Care
Innovation That Expands Access to Life-Saving Care
By Aura Moreno - Thu, 02/19/2026 - 09:47
Innovation should reach everyone who can benefit from it, says Phelippe Philippsen, Country Manager, Eli Lilly.
Novo Nordisk Launches Wegovy Pill for Weight Management
Novo Nordisk Launches Wegovy Pill for Weight Management
By Sofía Garduño - Fri, 01/16/2026 - 10:14
Novo Nordisk launches Wegovy pill in the United States, introducing the first oral GLP-1 option for weight management.
Eli Lilly Becomes First Drugmaker to Reach US$1 Trillion in Value
Eli Lilly Becomes First Drugmaker to Reach US$1 Trillion in Value
By Sofía Garduño - Fri, 11/21/2025 - 12:32
Eli Lilly becomes the first drugmaker to hit US$1 trillion, driven by demand for obesity drugs and expectations for orforglipron’s approval next year.
Eli Lilly Becomes First Drugmaker to Reach US$1 Trillion in Value
Eli Lilly Becomes First Drugmaker to Reach US$1 Trillion in Value
By Sofía Garduño - Fri, 11/21/2025 - 11:55
Eli Lilly becomes the first drugmaker to hit US$1 trillion, driven by demand for obesity drugs and expectations for orforglipron’s approval next year.